New Zealand -
English -
Medsafe (Medicines Safety Authority)
pimafucin
pharmaco (nz) ltd - natamycin - oral suspension - 1 % - active: natamycin
Armenia -
English -
Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
pimafucin tablets gastro-resistant
astellas pharma europe b.v. - natamycin - tablets gastro-resistant - 100mg
Armenia -
English -
Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
pimafucin cream for external use
temmler italia s.r.l. - natamycin - cream for external use - 20mg/g
United Kingdom -
English -
MHRA (Medicines & Healthcare Products Regulatory Agency)
locoid c ointment
astellas pharma ltd - chlorquinaldol; hydrocortisone butyrate - cutaneous ointment - 30mg/1gram ; 1mg/1gram
Ireland -
English -
HPRA (Health Products Regulatory Authority)
pimafucin eye
yamanouchi pharma ltd - ointment
Ireland -
English -
HPRA (Health Products Regulatory Authority)
pimafucin vaginal
yamanouchi pharma ltd - tablets
Ireland -
English -
HPRA (Health Products Regulatory Authority)
pimafucin vaginal
yamanouchi pharma ltd - tablets
India -
English -
Central Drugs Standard Control Organization
pimafucin 3ml eye dps
elder - natamycin - eye dps - 3ml
India -
English -
Central Drugs Standard Control Organization
pimafucin vaginal 3 tab
elder - natamycin - tab - 100mg - 3
United States -
English -
NLM (National Library of Medicine)
natacyn- natamycin suspension/ drops
eyevance pharmaceuticals, llc - natamycin (unii: 8o0c852cpo) (natamycin - unii:8o0c852cpo) - natacyn ® (natamycin ophthalmic suspension) 5% is indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including fusarium solani keratitis. as in other forms of suppurative keratitis, initial and sustained therapy of fungal keratitis should be determined by the clinical diagnosis, laboratory diagnosis by smear and culture of corneal scrapings and drug response. whenever possible the in vitro activity of natamycin against the responsible fungus should be determined. the effectiveness of natamycin as a single agent in fungal endophthalmitis has not been established. natacyn ® (natamycin ophthalmic suspension) 5% is contraindicated in individuals with a history of hypersensitivity to any of its components. safety and effectiveness in pediatric patients have not been established. no overall differences in safety or effectiveness have been observed be